SCHEMBL3003128

SCHEMBL3003128

O=C(O)C[C@@H]1COc2cc(O)ccc21

nearest known ligand 0.60

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARG P37231 13/20 0.60
PPARD Q03181 13/20 0.60
FFAR1 O14842 16/20 0.56
PPARA Q07869 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL204645 1.00 PPARG (0.60) PPARGPPARDFFAR1PPARA
SCHEMBL9979637 1.00 PPARG (0.60) PPARGPPARDFFAR1PPARA
SCHEMBL28279575 0.90 PPARG (0.52) PPARGPPARDFFAR1PPARA
SCHEMBL13524014 0.86 PPARG (0.46) PPARGPPARDFFAR1PPARA
SCHEMBL28121275 0.85 PPARD (0.53) PPARGPPARDFFAR1PPARA
SCHEMBL15153573 0.85 PPARG (0.45) PPARGPPARDFFAR1PPARA
SCHEMBL15292428 0.83 FFAR1 (0.69) PPARGPPARDFFAR1PPARA
SCHEMBL10011520 0.83 PPARG (0.59) PPARGPPARDFFAR1PPARA
SCHEMBL31674239 0.83 PPARD (0.59) PPARGPPARDFFAR1PPARA
SCHEMBL15299338 0.83 FFAR1 (0.69) PPARGPPARDFFAR1PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109491205-B Photosensitive resin composition and preparation method thereof 湖南五江高科技材料有限公司 2021-10-12 CN disclosed
CN-109575342-B Synthetic method of acrylic resin for photosensitive dry film 湖南五江高科技材料有限公司 2021-06-04 CN disclosed
EP-3105213-B1 DIHYDROBENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF DIABETES AND OBESITY TAKEDA PHARMACEUTICALS CO (JP) 2019-01-09 EP disclosed
EP-2803664-B1 TETRAHYDROBENZOFURANE DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF DIABETES JIANGSU HENGRUI MEDICINE CO (CN) 2018-11-21 EP disclosed
US-9969705-B2 Fused heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-15 US disclosed
EP-2838891-B1 AROMATIC RING COMPOUND AS GHRELIN O-ACYLTRANSFERASE INHIBITOR TAKEDA PHARMACEUTICALS CO (JP) 2017-08-02 EP disclosed
CN-104870429-B Benzofuran derivative, preparation method therefor, and medical application thereof 四川海思科制药有限公司 2017-05-03 CN disclosed
CN-104507921-B Benzocyclobutene derivative and preparation method and pharmaceutical application thereof 四川海思科制药有限公司 2017-02-22 CN disclosed
EP-3105213-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-12-21 EP disclosed
US-20160355494-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-08 US disclosed
EP-2248812-B1 FUSED CYCLIC COMPOUNDS AS GPR40 RECEPTOR MODULATORS TAKEDA PHARMACEUTICAL (JP) 2013-12-25 EP disclosed
US-8598226-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-12-03 US disclosed
US-20130267589-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2013-10-10 US disclosed
US-8492430-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-23 US disclosed
EP-2041123-B9 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2013-01-02 EP disclosed
US-20120302566-A1 INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-11-29 US disclosed
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 US disclosed
WO-2012081570-A1 LACTAM COMPOUND OR A SALT THEREOF, AND PPAR ACTIVATOR あすか製薬株式会社 (JP) 2012-06-21 WO disclosed
EP-2248812-A2 Fused cyclic compounds as GPR40 receptor modulators Takeda Pharmaceutical Company Limited (JP) 2010-11-10 EP disclosed
US-20100197761-A1 Fused cyclic compounds YASUMA TSUNEO 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267589-A1 FUSED CYCLIC COMPOUNDS GPR119, GLP1R, GPR65 PPARG 168/4885PPARD 128/4885FFAR1 15/4885
US-20160355494-A1 FUSED HETEROCYCLIC COMPOUND VIP, DPP4, TMPRSS15 PPARG 358/4885PPARD 942/4885FFAR1 1352/4885
US-20120302566-A1 INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS GPR119, INSR, GPR52 PPARG 149/4885PPARD 174/4885FFAR1 7/4885
US-20100197761-A1 Fused cyclic compounds GPR119, GLP1R, GPR65 PPARG 168/4885PPARD 128/4885FFAR1 15/4885
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF GPR119, INSR, GLP1R PPARG 155/4885PPARD 133/4885FFAR1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.